Cardiovascular outcomes trials with SGLT2 inhibitors

This module outlines CVOTs for empagliflozin (EMPA-REG OUTCOME®), canagliflozin (CANVAS Program) and dapagliflozin (DECLARE-TIMI 58) and ongoing SGLT2 inhibitor CVOTs for T2D.

Cardiovascular outcomes trials with SGLT2 inhibitors
Rate this content
  • Cardiovascular outcomes trials with SGLT2 inhibitors
  • A closer look at CV effects of 21st century T2D agents
  • CV safety trials are being conducted for each compound within the newer classes
  • Urinary glucose excretion via SGLT2 inhibition
  • Pharmacological properties of available SGLT2 inhibitors
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go